Triple

T4061237
Position Surface form Disambiguated ID Type / Status
Subject Center for Biologics Evaluation and Research E86214 entity
Predicate hasDivision P35 FINISHED
Object Office of Tissues and Advanced Therapies
The Office of Tissues and Advanced Therapies is a U.S. FDA office responsible for regulating cellular and gene therapies, tissue-based products, and other advanced biologic treatments.
E409911 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Office of Tissues and Advanced Therapies | Statement: [Center for Biologics Evaluation and Research, hasDivision, Office of Tissues and Advanced Therapies]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: Office of Tissues and Advanced Therapies
Context triple: [Center for Biologics Evaluation and Research, hasDivision, Office of Tissues and Advanced Therapies]
  • A. Human Tissue Authority
    The Human Tissue Authority is a UK regulatory body responsible for licensing and overseeing the removal, storage, use, and disposal of human bodies, organs, and tissue for purposes such as research, transplantation, and education.
  • B. Committee for Advanced Therapies
    The Committee for Advanced Therapies is a scientific body within the European Medicines Agency responsible for evaluating and providing expert opinions on advanced therapy medicinal products such as gene, cell, and tissue-engineered therapies.
  • C. Center for Cellular and Molecular Therapeutics
    The Center for Cellular and Molecular Therapeutics is a research institute specializing in developing gene and cell-based therapies for pediatric and genetic diseases.
  • D. NHS Blood and Transplant
    NHS Blood and Transplant is a UK special health authority responsible for providing a safe and reliable supply of blood, organs, and associated services to the National Health Service.
  • E. Office of Translational Sciences
    The Office of Translational Sciences is a scientific office within the U.S. Food and Drug Administration that advances the translation of biomedical research into safe and effective drug therapies through regulatory science, research, and policy development.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Office of Tissues and Advanced Therapies
Triple: [Center for Biologics Evaluation and Research, hasDivision, Office of Tissues and Advanced Therapies]
Generated description
The Office of Tissues and Advanced Therapies is a U.S. FDA office responsible for regulating cellular and gene therapies, tissue-based products, and other advanced biologic treatments.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07
Target entity: Office of Tissues and Advanced Therapies
Target entity description: The Office of Tissues and Advanced Therapies is a U.S. FDA office responsible for regulating cellular and gene therapies, tissue-based products, and other advanced biologic treatments.
  • A. Human Tissue Authority
    The Human Tissue Authority is a UK regulatory body responsible for licensing and overseeing the removal, storage, use, and disposal of human bodies, organs, and tissue for purposes such as research, transplantation, and education.
  • B. Committee for Advanced Therapies
    The Committee for Advanced Therapies is a scientific body within the European Medicines Agency responsible for evaluating and providing expert opinions on advanced therapy medicinal products such as gene, cell, and tissue-engineered therapies.
  • C. Center for Cellular and Molecular Therapeutics
    The Center for Cellular and Molecular Therapeutics is a research institute specializing in developing gene and cell-based therapies for pediatric and genetic diseases.
  • D. NHS Blood and Transplant
    NHS Blood and Transplant is a UK special health authority responsible for providing a safe and reliable supply of blood, organs, and associated services to the National Health Service.
  • E. Office of Translational Sciences
    The Office of Translational Sciences is a scientific office within the U.S. Food and Drug Administration that advances the translation of biomedical research into safe and effective drug therapies through regulatory science, research, and policy development.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69aed93c69208190a4efac0efe3cd69b completed March 9, 2026, 2:29 p.m.
NER Named-entity recognition batch_69aefbd4acb0819093bcffcd05ed8e6f completed March 9, 2026, 4:56 p.m.
NED1 Entity disambiguation (via context triple) batch_69b562ac25848190951431c9c853cc59 completed March 14, 2026, 1:29 p.m.
NEDg Description generation batch_69b5633103e081909dbe7a7e54877343 completed March 14, 2026, 1:31 p.m.
NED2 Entity disambiguation (via description) batch_69b563eca17c81908deff0d361a7be87 completed March 14, 2026, 1:34 p.m.
Created at: March 9, 2026, 3:38 p.m.